Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is an active treatment, extended access study open solely to those subjects who have
successfully completed the Core and Repeat Dosing portions of the MT-3724_NHL_001_US clinical
study and who, in the investigator's judgment, (i) have not had progressive disease while on
MT-3724 treatment (i.e.; have shown a complete or partial response or stable disease), (ii)
have experienced no clinical or laboratory toxicities that would contraindicate further
MT-3724 dosing and (iii) have no acceptable and better alternative treatment available to
them.